- A Study Evaluating APG777 in Atopic Dermatitis — Active Not Recruiting • Phase II • Dermatology • NCT06395948.
- Trial testing a new drug (APG777) to treat moderate-to-severe eczema, comparing different doses against placebo over 106 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B. Conditions: Atopic Dermatitis Interventions: APG777, Placebo Lead Sponsor:…